The formulation of liposomal GP2 elicited robust CD8+ T-cell responses, and both systems resulted in significantly smaller tumor sizes and longer survival times in both prophylactic and therapeutic settings compared to other treatment groups. This evidence concerns the gene CD8A and neoplasm.